$-0.41 EPS Expected for Corium International, Inc. (CORI) on May, 10

April 17, 2018 - By Russell Jones

During 2017 Q4 the big money sentiment decreased to 1.79. That’s change of 1.88, from 2017Q3’s 3.67. 5 investors sold all, 14 reduced holdings as Corium International, Inc. ratio turned negative. 20 increased stakes while 14 funds bought stakes. Funds hold 30.74 million shares thus 50.54% less from 2017Q3’s 62.14 million shares.
Credit Suisse Ag reported 11,679 shs or 0% of all its holdings. Emory University stated it has 1.39% in Corium International, Inc. (NASDAQ:CORI). California Public Employees Retirement Sys owns 32,277 shs or 0% of their US capital. Millennium reported 88,861 shs. Iguana Health Management Ltd Company holds 90,000 shs. Geode Capital Mngmt Limited Liability reported 0% in Corium International, Inc. (NASDAQ:CORI). Tiaa Cref Inv Lc has invested 0% in Corium International, Inc. (NASDAQ:CORI). Needham Ltd Com has 1.12% invested in Corium International, Inc. (NASDAQ:CORI). Intll Grp holds 0% of its capital in Corium International, Inc. (NASDAQ:CORI) for 16,393 shs. Rhumbline Advisers holds 0% of its capital in Corium International, Inc. (NASDAQ:CORI) for 18,281 shs. Barclays Public Limited Co reported 0% of its capital in Corium International, Inc. (NASDAQ:CORI). Legal General Grp Public Limited Liability Corp accumulated 4,122 shs or 0% of the stock. State Common Retirement Fund stated it has 0% in Corium International, Inc. (NASDAQ:CORI). Morgan Stanley invested in 0% or 52,607 shs. Retail Bank Of New York Mellon Corp accumulated 84,925 shs or 0% of the stock.

Corium International, Inc. (NASDAQ:CORI) is awaited to reveal earnings on May, 10., Zacks reports. Analysts predict 2.38 % diference or $-0.41 from the $-0.42 EPS from 2017. Wall Street now forecasts 10.81 % negative EPS growth despite Corium International, Inc. last quarter’s EPS of $-0.37. The stock decreased 2.72% or $0.29 during the last trading session, reaching $10.38.Corium International, Inc. has volume of 169,863 shares. Since April 17, 2017 CORI has risen 192.37% and is uptrending. CORI outperformed by 180.82% the S&P500.

Corium International, Inc. (NASDAQ:CORI) Ratings Coverage

Total analysts of 4 have positions in Corium (NASDAQ:CORI) as follows: 4 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since October 27, 2017 according to StockzIntelligence Inc Corium has 11 analyst reports. The stock rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, November 16. In Friday, November 17 report Jefferies maintained it with “Buy” rating and $13.0 target. In Thursday, March 8 report Cantor Fitzgerald maintained it with “Buy” rating and $14.0 target. On Friday, October 27 the firm has “Buy” rating given by Jefferies. The stock rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, March 27. On Monday, November 20 Needham maintained Corium International, Inc. (NASDAQ:CORI) with “Buy” rating. On Friday, December 22 Cantor Fitzgerald maintained Corium International, Inc. (NASDAQ:CORI) rating. Cantor Fitzgerald has “Buy” rating and $14.0 target. On Friday, February 9 the stock has “Buy” rating by Cantor Fitzgerald. On Friday, November 17 H.C. Wainwright maintained Corium International, Inc. (NASDAQ:CORI) rating. H.C. Wainwright has “Buy” rating and $15.0 target. The company rating was maintained by H.C. Wainwright on Friday, February 9.

Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems.The firm is worth $374.97 million. It offers Clonidine Transdermal Delivery System , a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.Last it reported negative earnings. The company??s products under pipeline comprise Twirla, a combination hormonal contraceptive patch, which has completed Phase III clinical trials to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trials for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trials for the treatment of Alzheimer's disease.

Corium International, Inc. (NASDAQ:CORI) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.